Can I change from truvada to descovy on pep with raltegravir?

The short version: raltegravir plus emtricitabine/tenofovir is a studied PEP backbone, but nothing in this retrieval tested swapping Truvada for Descovy, so the switch is plausible, not proven.

The closest match is a 28-day nonrandomized study of raltegravir plus emtricitabine/tenofovir (the old tenofovir, TDF, the same drug in Truvada) in HIV-negative men after sexual exposure: 92% finished the course, 89% took it as prescribed, and nobody caught HIV [4]. That is real but weak evidence. It was not randomized, it compared people by risk group, and it was not run against a true placebo [4]. The newer tenofovir (TAF, the one in Descovy) shows up in a separate retrospective PEP study paired with a different drug, where completion and side effects were similar to the older backbone [1]. Neither study isolates the Truvada-to-Descovy swap you are asking about.

Raltegravir has no major interaction with tenofovir or emtricitabine in the pharmacology reviews here [2][3]. The muscle-enzyme signal with raltegravir is worth knowing: five men on raltegravir plus FTC/TDF had grade 4 creatine kinase (a muscle breakdown marker), all resolving without stopping the drug [4]. TAF carries less kidney and bone exposure than TDF in general practice, but this retrieval contains no head-to-head PEP trial of the two.

My call: switching is reasonable if your clinician agrees, but the specific Truvada-to-Descovy swap on raltegravir PEP has not been directly tested in these records, so treat it as a judgment call, not an evidence-backed upgrade. Confidence: low.